2026 Bulk Price 3-[(1S)-1-(Dimethylamino)Ethyl]Phenol Manufacturer
- Industrial Scale Supply: Capable of delivering multi-ton quantities with consistent industrial purity exceeding 98.0%.
- Cost Efficiency: Significant reduction in bulk price per kilogram compared to laboratory-scale reagent procurement.
- Regulatory Compliance: Full documentation including COA, stability data, and optimized synthesis route validation.
The pharmaceutical intermediate known as (S)-3-[1-(Dimethylamino)ethyl]phenol serves as a critical chiral building block in the production of acetylcholinesterase inhibitors. As the global demand for neurodegenerative disease treatments escalates toward 2026, procurement strategies must shift from milligram-scale reagent purchasing to metric-ton industrial sourcing. This transition requires a partner capable of maintaining strict stereochemical integrity while optimizing cost structures for large-scale API manufacturing.
At NINGBO INNO PHARMCHEM CO.,LTD., we specialize in the scale-up of complex chiral intermediates. Our production facilities are engineered to handle the specific thermal and handling requirements of phenolic amines, ensuring that the physical form remains a stable crystalline powder with a melting point consistent with theoretical specifications around 119°C. Understanding the nuances of this molecule is essential for procurement managers looking to secure supply chains against future volatility.
Wholesale Pricing Tiers vs Sigma-Aldrich mg Scale
Historically, many process development teams rely on general chemical reagent suppliers for early-stage clinical material. While acceptable for gram-scale synthesis, this approach becomes financially unsustainable during commercial manufacturing. The price disparity between reagent-grade packages and industrial bulk quantities is substantial. Reagent suppliers often charge a premium for packaging, handling, and low-volume logistics, which inflates the cost per kilogram by several orders of magnitude.
In contrast, a dedicated global manufacturer offers pricing tiers that reflect true production economics. When producing Rivastigmine Related Compound C or the target phenol intermediate at scale, the cost drivers shift from packaging to raw material sourcing and reaction yield optimization. Our industrial processes utilize continuous flow chemistry and advanced crystallization techniques to maximize yield while minimizing solvent waste. This efficiency allows us to offer competitive bulk price structures that reagent suppliers cannot match.
For example, while small-scale providers may list purity specifications of ≥98.0% using GC or Titration methods, they often lack the batch consistency required for GMP API production. Industrial sourcing ensures that every drum meets the same rigorous specifications, reducing the risk of batch failure during downstream coupling reactions. Procurement officers should calculate the total cost of ownership, including quality control testing and potential yield loss, rather than focusing solely on the invoice price of small packages.
MOQ and Global Logistics for 25kg Drums
Logistics and minimum order quantities (MOQ) are pivotal considerations when transitioning to commercial supply. Standard industrial packaging for this intermediate typically involves 25kg fiber drums or high-density polyethylene containers lined with moisture-proof bags. Phenolic compounds can be sensitive to oxidation and moisture absorption, so proper sealing is critical to maintain the white crystalline physical form during transit.
Our logistics network supports global shipment with full customs documentation. Unlike smaller suppliers who may struggle with hazardous material classifications for bulk amines, we manage the entire export process compliantly. When sourcing high-purity 3-[(1S)-1-(Dimethylamino)ethyl]phenol, buyers should verify that the supplier can provide consistent lead times for multi-drum orders. Supply chain resilience is built on the ability to forecast demand and secure production slots months in advance.
Quality assurance is maintained through comprehensive documentation. Every shipment is accompanied by a detailed COA (Certificate of Analysis) that verifies specific rotation, purity via HPLC or GC, and residual solvent levels. The table below outlines the typical industrial specifications we maintain for bulk orders compared to standard reagent grades.
| Specification Parameter | Industrial Bulk Standard | Reagent Grade Typical |
|---|---|---|
| Purity (GC/HPLC) | ≥ 98.5% | ≥ 98.0% |
| Physical Form | Crystalline Powder | Crystalline Powder |
| Melting Point | 118°C - 120°C | 119°C (Ref) |
| Packaging | 25kg Drum (Moisture Protected) | 1g - 100g Bottle |
| Lead Time | 2-4 Weeks (Bulk) | Immediate (Stock) |
2026 Market Forecast for Rivastigmine Intermediates
The market trajectory for chiral phenol intermediates is closely tied to the production volumes of Alzheimer's and Parkinson's disease medications. As patents expire and generic formulations enter new markets, the demand for cost-effective intermediates like (S)-3-(1-(Dimethylamino)ethyl)phenol is projected to rise steadily through 2026. Manufacturers who secure long-term supply agreements now will be better positioned to manage margin pressures in the future.
Our synthesis route is designed for scalability, utilizing readily available starting materials to mitigate raw material price fluctuations. We anticipate that environmental regulations regarding solvent usage will tighten, favoring manufacturers who have already invested in green chemistry processes. NINGBO INNO PHARMCHEM CO.,LTD. remains committed to sustainable manufacturing practices, ensuring that our clients meet their own ESG (Environmental, Social, and Governance) goals while procuring essential materials.
Furthermore, the shift towards continuous manufacturing in the pharmaceutical industry requires intermediates with exceptionally low variability. Batch-to-b consistency in stereochemical excess is non-negotiable. Our quality control laboratories employ chiral HPLC methods to verify enantiomeric purity before release. This level of scrutiny ensures that downstream synthesis steps proceed without unexpected deviations, protecting the overall yield of the final API.
In conclusion, securing a reliable supply of this critical intermediate requires a partnership with a manufacturer who understands both the chemistry and the commercial landscape. By focusing on industrial purity, scalable logistics, and transparent pricing, we support our partners in delivering vital medications to patients worldwide. Contact our technical sales team to discuss volume requirements and secure your allocation for the 2026 production cycle.